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LipidsLiver X receptor (LXR)α and LXRβ belong to the nuclear receptor superfamily. For many years, they have been
called orphan receptors, as no natural ligand was identiﬁed. In the last decade, the LXR natural ligands have
been shown to be oxysterols, molecules derived from cholesterol. While these nuclear receptors have been
abundantly studied for their roles in the regulation of lipid metabolism, it appears that they also present
crucial activities in reproductive organs such as testis and epididymis, as well as prostate. Phenotypic analyses
of mice lacking LXRs (lxr−/−) pointed out their physiological activities in the various cells and organs
regulating reproductive functions. This review summarizes the impact of LXR-deﬁciency in male
reproduction, highlighting the novel information coming from the phenotypic analyses of lxrα−/−,
lxrβ−/− and lxrα;β−/−mice. This article is part of a Special Issue entitled: Translating nuclear receptor from
health to disease.slating nuclear receptors from
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In the early 90's, the discovery of numerous nuclear receptors,
called “orphan” since no bona ﬁde ligand had been identiﬁed, opened
the way of the reverse endocrinology [1]. In contrast to classical
endocrinology where the effector is discovered following the study of
its hormone, the nuclear receptor is used to screen for ligands, either
natural or not, which modulate its transcriptional activity. The ligand,
in turn, is used as a chemical tool to dissect the role of its nuclear
receptor in physiology and pathophysiology [2]. Over the past decade,
reverse endocrinology has been used to link several orphan receptors
to ligands and biological functions. Such philosophy has led to the
identiﬁcation of liver X receptors (LXRs) α ([3]; NR1H3) and β ([4,5];
NR1H2) as oxysterol receptors [6,7], and to deciphering of their
physiological functions. In turn, synthesis of non-metabolisable
molecules modulating their transcriptional activity, permitted the
investigations of their putative interest as pharmacological targets [8].LXRα and LXRβ form obligatory heterodimers with retinoid
receptors (RXR, NR2B1-3), the receptors of 9-cis retinoic acid [3,9].
LXRβ was found to be expressed in many tissues, whereas LXRα is
expressed mainly in a restricted subset of tissues known to play an
important role in lipid metabolism (such as liver, small intestine,
kidney, spleen, and adipose tissue; for a review, see Ref. [10]). In
absence of ligand, LXRs constitutively bind to RXRs and speciﬁc
binding sequences localized on target gene promoters [3], together
with co-repressors, which block transcription by recruitment of
histone deacetylase. Hence, the presence of the complex [RXR/LXR-
corepressor-histone deacetylase] on the DNA usually acts as a basal
repressor of gene transcription [9]. Oxysterol or 9-cis retinoic acid
binding to their respective nuclear receptors leads to modiﬁcations of
the ligand binding pocket within the carboxy-terminus domain. This
induces the release of the co-repressors and reinforces the interac-
tions with the co-activators [11]. This cascade of events allows the
recruitment of proteins with acetyl-transferase activity and a
permissive chromatin environment, which ﬁnally enhances LXR-
target gene expression and thus the physiological response of the cell.
A large number of natural LXR ligands have been described, such as
oxidized derivatives of cholesterol (for a review, see Refs. [12,13]). In
mammals, themain source of oxysterols remains endogenous production
[13]. An important enzymeof this pathway is the sterol 14α-demethylase
(EC 1.14.13.70, CYP51), a cytochrome P450 required for sterol biosyn-
thesis in different phyla, and the most widely distributed P450 gene
family being found in all biological kingdoms [14]. It catalyzes the ﬁrst
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Fig. 1. Schematic representation of cholesterol synthesis and metabolism into androgens or bile acids. 3-Hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase is the rate-
controlling enzyme of the mevalonate pathway that produces cholesterol and other isoprenoids. This synthesis could virtually occur in all cells. Androgens synthesis mainly takes
place in Leydig cells, bile acids synthesis in hepatocytes. Structures of the main sterols are indicated: lanosterol, cholesterol, T-MAS, 22(R)-OH-cholesterol and 7α-OH-cholesterol.
For more details about the indicated enzymes, see text. StAR, steroidogenic acute regulatory protein; CYP51, 14α-demethylase; CYP7A1, cytochrome P450 cholesterol
7α-hydroxylase; CYP11A1, cytochrome P450 side chain cleavage; CYP17, cytochrome P450 17α-hydroxylase/17,20-lyase; 3βHSD, 3β-hydroxysteroid dehydrogenase type 2.
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alpha-methyl group from lanosterol in the cholesterol biosynthetic
pathway (Fig. 1). Interestingly, although the human 14α-demethylase
gene is expressed in a variety of tissues, the highest levels are observed in
testis, ovary, adrenal, prostate, liver, kidney, and lung. In the reproductive
tract, many activating oxysterols are present (for a review, see Ref. [13]):
including 22(R)-hydroxycholesterol (within the steroidogenic pathway),
follicularﬂuidmeiosis-activating sterol (FF-MAS), and its derivative, testis
meiosis-activating sterol (T-MAS).
Due to the lipid nature of the ligands, the physiological roles of LXRs
have been extensively detailed in the homeostasis of cholesterol in the
gut-liver axis [15]. The role of the LXRs on cholesterol metabolism was
determined using engineered knock-out mice lacking one (lxrα−/− or
lxrβ−/−) or both (lxrα;β−/−) isoforms. Historically, the ﬁrst analyses
were performed on the lxrα−/− mice, which developed a hepatic
steatosis, due to cholesteryl-ester accumulationwhen fed a cholesterol-
rich diet [16]. The molecular mechanism leading to this phenotype was
the lackof upregulation of cyp7a1encoding for the rate-limiting enzyme
for the metabolism of cholesterol into bile acid (Fig. 1). Lxrβ−/− [17]
and lxrα;β−/− [17,18]micewere then obtained. The role of the LXRs in
cholesterol metabolism was thus extended to de novo synthesis of
cholesterol [19], excretion [16] and detoxiﬁcation of bile acids [20] orlipids [21], as well as in glucose homeostasis [22], immunity [23], skin
development andhomeostasis [24] andbrain functions [25,26]. LXRs, by
regulating expression of several genes (including ABCA1 [18,27], ABCG1
[28], apolipoprotein E (APOE) [29], and PLTP [30]) also play a critical role
in reverse cholesterol transport. Interestingly, activation of LXRs in
intestine and macrophages efﬁciently prevents atherosclerosis [31,32].
This review will emphasize the physiological roles of LXRs in the male
and thus focus on testis, epididymis and prostate (Fig. 2).
The hypothesis that LXRs could also have physiological roles in
steroidogenic and reproductive tissues came from difﬁculties in
maintenance of the mouse colony, as well as from previous studies
performed on the adrenals [33,34]. LXRα-deﬁcient mice presented an
adrenomegaly due to a higher cholesteryl-ester content and a Cushing-
like syndrome, as shown by the increased levels of blood corticosterone
[33]. This work emphasized the role of LXRα as an important regulator
of adrenal cholesterol homeostasis through its ability to modulate
transcription of genes that govern the three major pathways of adrenal
cholesterol, namely efﬂux, storage, and conversion into steroid
hormones [33]. In vivo studies also showed that LXRα- and LXRβ-
deﬁcient mice had reduced fertility, characterized by less frequent
conception and lower number of pups per litter [35,36]. Careful
examination conﬁrmed that both sexes were affected by reproductive
Fig. 2. Physiological roles of LXRs in male genital tract. Three main organs are targeted by LXR-disruption in male mice: testis, epididymis, and prostate. Schematically, LXRs regulate
lipid homeostasis in testis and epididymis, as well as apoptosis–proliferation equilibrium of spermatozoa (spz), testicular germ cells and prostate epithelium. For more details, see
text.
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syndrome [37], a syndrome characterized in women by ovarian
enlargement associated with an extra-vascular ﬂuid concentration,
haemorrhagic ovarian corpora lutea and elevated estradiol serum levels
[38,39], as well as ii) parturition defects due to abnormal uterine
contraction [40]. LXR-deﬁcient males present abnormal features both
within the testis and epididymis (see following chapter). Besides,
experiments performed on human cell culture suggested that LXRs
could have a protective effect in prostate cancer (see Chapter 4.1).
2. LXRα and LXRβ are involved in various physiological processes
in the testis
Investigation of LXR-double knock-out mice revealed a decreased
fertility at 5 months of age and evolving to complete infertility by
9 months [35,36]. Several testicular functions have been found
impaired in LXRα- and LXRβ-deﬁcient mice: (1) steroidogenesis,
(2) lipid metabolism and (3) proliferation–apoptosis balance in germ
cells (Fig. 2).
Quantitative PCR analysis of both LXR isoforms showed that LXRα
is expressed in Leydig cells, while LXRβ was found in Sertoli cells,
suggesting a speciﬁc role of each isoform. Both LXRs are present in the
germ cells.
2.1. LXRα is involved in germ cell apoptosis while LXRβ controls
their proliferation
Spermatogenesis is maintained by a delicate balance between
proliferation, differentiation, and death of germ cells. Alteration of
these processes results in spermatogenic impairment and thus
infertility. Both proliferation and apoptosis were found altered in
LXR-deﬁcient mice [36].
Analysis of the single LXR-KO mice showed that LXRα is involved
in the regulation of apoptosis in the testis [36]. TUNEL analyses
revealed that lxrα−/− (as well as lxrα;β−/−) mice had a signif-
icantly higher number of apoptotic cells compared with wild-type
mice, whereas a slightly but not signiﬁcantly decreased number of
apoptotic cells was observed in lxrβ−/− mice. Consistent with these
data, mRNA expression analyses showed a higher accumulation of the
proapoptotic transcript Bad, as well as TNFα in LXRα-lacking mice.
Conversely, LXRβ-deﬁcient (as well as lxrα;β−/−) mice had a
signiﬁcantly lower number of proliferating cells [36] and cyclinA1mRNA accumulation, suggesting that LXRβ is involved in germ cell
proliferation. Infertility and destructured testis were observed only
when both isoforms were absent [36]. A schematic view of a testis
tubule with the various cells and the proteins, whose accumulation
was altered, is given in Fig. 3.
2.2. LXRα controls androgen synthesis in testis
The hypothesis that LXRα could regulate androgen production came
from the decreased level of testicular testosterone observed in lxrα−/−
and lxrα;β−/− mice [36]. Type 1 3β-hydroxysteroid dehydrogenase
isomerase (3βhsdI) mRNA accumulation was the most affected of the
mRNA encoding the steroidogenic proteins (Fig. 3), whereas levels of
steroidogenic acute regulatory protein (StAR) and the cytochrome 11a1
(cyp11a1) and 17 (cyp17) transcripts remained unchanged (refer to Fig.
1 for the proteins).Moreover, signiﬁcantly lower plasma concentrations
of luteinizing hormone (LH) were found in LXRα-deﬁcient mice [36].
Thesedatawere conﬁrmedby lower level of expressionof the speciﬁcβ-
chain of LH in the pituitary of these animals. Additionally, LXRα-
deﬁcient mice were able to respond to human chorionic gonadotropin
challenge by an increased production of testosterone similar to their
wild-type controls. Interestingly, LXR agonist T0901317 increased
testosterone concentration inwild-typemice (almost 14-fold compared
to the vehicle-gavaged mice), as well as accumulation of StAR at both
mRNA and protein levels. Together, these data indicate that LXRα
regulates steroid synthesis not only in adrenal cells [33] but also in
Leydig cells [36].
2.3. Both LXRα and LXRβ play a crucial role in lipid homeostasis
in the testis
Part of the phenotype observed in the LXR-deﬁcient mice was
correlatedwith an alteration of lipid homeostasis [35,36,41]. Themain
enzymes involved in the fatty acid pathway are indicated on Fig. 4.
mRNA levels of sterol response element binding protein-1c (srebp1c)
and fatty acid synthase (fas, Fig. 4), encoding the sterol response
element binding protein-1c and the fatty acid synthase, respectively,
were decreased by 40% in lxrα;β−/− mice (Fig. 3) compared to the
wild-type mice [36]. In contrast, the level of scd1, encoding the
stearoyl CoA-desaturase 1 (Fig. 4), was increased by 2-fold in LXR-
deﬁcient mice (Fig. 3), while srb1, encoding the scavenger receptor
B1, abca1 (ATP-binding cassette, sub-family A member 1), and scd2
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an accumulation of lipids in the Sertoli cells and in spermatids of LXR-
deﬁcient mice. These observations conﬁrmed that fatty acid metab-
olism is important for reproductive functions, as previously reported
[42]. It could also be concluded that lipid homeostasis alteration was
the ﬁrst event in this long process of testis disorganization in
lxrα;β−/− mice [36], as suggested by Mascrez et al. [35].
Our data also showed that the lack of both LXRα and LXRβ leads to
an increase of RARα and RARβ (all-trans retinoic acid receptors,
NR1B1 and NR1B3), and retinaldehyde dehydrogenase-2 (RALDH-2)
expressions [36] (Fig. 3), resulting in deregulation of retinoic acid
signaling. This is seen in the expression pattern of known RAR-target
genes, such as dosage suppressor of mck1 homolog, meiosis-speciﬁc
homologous recombination (dmc1) and synaptonemal complex
protein 3 (scp3), and could lead to spermatogenic disorders. Lipid
accumulation has previously been observed in rat Sertoli cells in
hypervitaminosis A [43], suggesting links between retinoid and lipid
pathways. How the lack of LXRs act upon the retinoic acid signaling
pathway remains to be clariﬁed; however, it could be hypothesized
that SHP (small heterodimeric partner, NR0B2), a non-canonical
orphan nuclear receptor, could play a major role as shown by Volle
et al. [44,45] by studying SHP-deﬁcient mice. Indeed, SHP has been
described to be a negative regulator of a number of nuclear receptors
such as LXRs and RARs [46].
Phenotypic analysis of lxr−/− mice has thus shown that
cooperation between LXRα and LXRβ maintains both testis structure
and function. In human, Chen et al. [47] identiﬁed and characterized
two alternative spliced transcript variants of LXRα. LXRα2, which
has a shorter N-terminal domain and a reduced transcriptional
activity, was found highly expressed in testis. The physiological role of
the shorter form remains to be deﬁned in man. Since ablation of LXRs
impairs the fertility of aging mice, a putative defect in LXR-signaling
cannot be excluded in the premature loss of fertility observed in
some men.
3. LXR-deﬁcient mice present abnormal features of the epididymis
As described above, lxrα;β−/− male mice become completely
infertile when the animals reach the age of 9 months. The infertilityarises from the association of testicular alterations [36] with an
epididymal destructuration [48] observed in the two ﬁrst segments of
the organ (for a schematic representation see Fig. 5), which functions
in regulation of the cholesterol homeostasis and maturation of
spermatozoa. The phenotype observed in the lxrα;β−/− mice is
characterized by an enlargement of the tubule lumen, with the
presence of an amorphous substance in the lumen and shrinkage of
the epithelial height. Interestingly, a 15-day supplementation with
androgens could not reverse the phenotype. Oil-red-O staining of
caput epididymidis cryosections reveals lipid accumulation in the
peritubular and interstitial tissues and the epithelium of lxrα;β−/−
male mice. The amorphous substance in the tubule lumen was not
stained, thus indicating that it was not composed of neutral lipids.
Many isolated spermatozoa heads and ﬂagella were observed when
sperm were retrieved from the cauda epididymidis, revealing that the
gametes were fragile, probably as a result of both testicular and
epididymal dysfunctions [48]. The expression levels of genes
regulating the fatty acid metabolism also seemed to be affected
since quantitative real time RT-PCR showed that srebp1c, scd1 and
scd2 mRNAs were decreased in lxrα;β−/− male caput epididymidis
Fig. 5. Schematic representation of the role of LXRs in the caput epididymidis. Epididymis is organized in three parts (caput, corpus and cauda). Themain cells are indicated. Themajor
phenotype of the LXR-deﬁcient mice is observed in the segments I and II of the caput with the lack of ABCA1 (indicated in red) in the apical membrane of the apical cells. Latin
numerals indicate the caput segments.
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regulations was moderate as they do not inﬂuence fatty acid
compositions of separated phospholipid and neutral lipid fractions
in lxrα;β−/− animals [49]. Further investigations revealed that
cholesterol trafﬁcking was a LXR-regulated mechanism in mouse
caput epididymidis, in a segment- and cell-speciﬁc manner [50]. In
LXRα- and LXRβ-deﬁcient animals, apical cells present in the two ﬁrst
caput segments had their cytoplasm ﬁlled with cholesteryl-ester
droplets, in associationwith a loss of ABCA1 in the apical membrane of
the apical cells (Fig. 5). The level of apoptotic apical cells was also
increased in lxrα;β−/− compared to wild-type mice. ABCA1 was thus
conﬁrmed to be an important factor in the male reproductive tract,
as male mice invalidated for this gene were previously shown to have
a 21% fertility decrease over their lifespan. Both expression and
location of ABCG1 were different from ABCA1 and were not altered
in the epididymis of LXR-deﬁcient mice. ABCG1 was present at the
apical pole of all epithelial cells in the proximal caput epididymal
segments [50], suggesting complementary functions for these
two cholesterol transporters in the epididymal epithelium. These
locations raise the question how cholesterol efﬂux could be involved
in sperm maturation.
Even though germ cells already presented abnormal lipid
accumulation in the testis [36], alterations of cholesterol homeosta-
sis may also be linked to sperm maturation defects along the
epididymal duct and lead to impaired fertility. In man, dyslipidemia,
obesity and/or hypercholesterolemia are generally associated with
testicular defects and endocrine perturbations whereas defaults in
epididymal sperm maturation are rarely investigated in these
situations. Recent data showed that fertile three month-old
lxrα;β−/− male mice became infertile when fed a 1.25% cholesterol
containing diet during four weeks. An atherosclerosis-like process
was observed in the proximal epididymis, provoking sperm
morphological abnormalities, decreased motility and viability and
premature acrosome reaction (Ouvrier et al. submitted). This study
brings forward the epididymis as an early target of cholesterol
toxicity in a dyslipidemic mouse model, and shows that post-testicular sperm alterations may be associated with male infertility
under dyslipidemic conditions.
4. Physiological role of LXRα and LXRβ in prostate cancer
Prostate cancer is the most frequently diagnosed cancer and the
leading cause of death from cancer in men over 50 years old. Among
the various genetic and environmental risk factors, epidemiological
analyses have revealed a positive association between hypercholes-
terolemia and the development of prostate cancer [51,52]. Indeed,
epidemiological studies have shown that Chinese populations, with a
low risk to develop prostate cancer, had an increased risk after
migration to the United States. This environmental effect was
attributed to the deleterious impact of lipid consumption on this
cancer [53]. Actually, cholesterol accumulation in tumors was ﬁrst
reported in the early 20th century [54] without any clear mechanistic
explanation [55]. One of the various hypotheses was that rapidly
proliferating cancer cells require new components to build de novo
plasma membrane. Consistent with this hypothesis, HMG-CoA
reductase inhibitors that impede de novo synthesis of cholesterol
block prostate cancer cell growth in vitro [56]. Statins and their
derivatives have thus been suspected to have beneﬁts in prostate
cancer progression in patients undergoing long-term treatment
[57–59]. Even though LXRs are key-sensors of cholesterol homeostasis,
their role in prostate physiology remains poorly understood.
4.1. Both LXRα and LXRβ modify the apoptosis–proliferation balance in
prostate cancer cells
Fukuchi et al. [60] ﬁrst reported the control of proliferation by LXRs
on LNCaP human prostate carcinoma cell line, in vitro aswell as in vivo.
In their experiments, LXR agonist T0901317 decreased the percentage
of cells in S-phase through an upregulation of p27kip1. The induction of
expression of the cholesterol membrane transporter ABCA1 by
T0901317 led to the assumption that ABCA1 was the key-regulator
of the cell cycle in response to LXR activation [61]. Freeman and
ABC
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Growth factors
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Growth factor receptors
LXR-ligandCell survival Cell death
Fig. 6. Role of LXRs in apoptosis of prostate human cancer cells. A)When the level of cholesterol is high, it accumulates in membranes within the lipid rafts, which allows the growth
factors to access to their receptors. Binding of these peptides increases cell proliferation and inhibits cell death by apoptosis. B) Activation of LXRs by its ligand induces a higher
production of ATP-binding cassettes (ABC) involved in cholesterol efﬂux, which destructures the lipid rafts. Growth factors are less efﬁcient to maintain cell proliferation, which in
turn increases apoptosis. Broken arrow indicates an inhibition.
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membrane was required to allow raft coalescence [62]. Sequestration
of “oncogenic” signaling proteins in a restricted area through raft
coalescence could enhance their activity by exclusion of negative
regulators outside the rafts [63,64]. Based on that hypothesis, we
explored whether LXRs could modulate cholesterol concentration in
rafts [65]. In vitro and in vivo analyses revealed that modulation of LXR
activity triggered apoptosis of prostate cancer cells. This effect
involves both the increase of cholesterol efﬂux by ABC proteins and
the disruption of lipid-rafts signaling activity. Schematically (Fig. 6),
LXRs ﬁrst mediate upregulation of ABCG1 that stimulates reverse
cholesterol transport. This results in a reduction in plasma membrane
cholesterol steady state levels. Then, both disruption of lipid-rafts and
down-regulation of raft-associated signaling in prostate cancer cells
are induced, together with a decrease in the phosphorylated fraction
of raft-associated AKT. Cholesterol replenishment prevents entry of
the cells into apoptosis in the presence of T0901317 demonstrating
that cholesterol homeostasis regulation by LXRs is a key-process to
control cell death. Consistent with this mechanism, chronic T0901317
treatment down regulates AKT and stimulates apoptosis of LNCaP
derived tumors in xenografted mice [65]. These results pointed out
that LXRα and LXRβ are important modulators of prostate cancer cell
survival. Altogether, these ﬁndings reinforce the idea to consider LXR
agonists as potential pharmacological agents in cancer prevention and
anti-cancer therapy (for a review, see Ref. [66]). Various studies
indeed enlighten the anti-proliferative and proapoptotic effects of
LXR-ligand on ovarian [67] and breast [68,69] cancer models.4.2. LXRα and benign prostatic hyperplasia
Benign prostatic hyperplasia concerns 50% of men over the age
of 50 years [70]. Symptoms include urinary frequency, urgency
incontinence (compelling need to void that cannot be deferred),
and voiding at night (nocturia) [71]. Kim et al. [72] showed that
LXRα−/− mice presented benign prostatic hyperplasia-like features
on ventral prostate such as proliferative epithelial cells, multiple
layers of dense stroma around the prostatic ducts and dilated prostatic
ducts. These data suggest that LXRα agonists could also be useful in
the treatment of this potentially harmful pathology since some
patients may eventually progress to renal failure.5. Are LXRs promosing pharmacological targets in
human diseases?
The discovery of new regulated transcription factors has always
opened severalﬁelds of investigation. Fromanacademic point of view, it
is elegant to identify novel bona ﬁde genes and associate the discovered
factor to newphysiological functions. The use of transgenic animals (ﬂy,
mouse, worm…) usually helps in linking abnormal features of the
transcription factor (mutation or abnormal signaling pathway) to
human diseases. At last, once this milestone is reached, chemists can
synthesize thousands of new ligands in order to modulate the protein
activity. However, the main concern for pharmacology researchers is to
solve the pathological problem without opening Pandora's box to
optimize the ligands of therapeutical interest without inducing major
side effects (for a review, see Ref. [66]).
Studies on mice pointed out that LXR-deﬁciency could be
associated with several phenotypes resembling putative diseases
found in human such as metabolic disorders, reproductive failures,
central nervous system alterations, or various types of cancer [66].
Clinical use of LXR agonists should thus theoretically be useful in
reducing cholesterol levels, neural degeneration, parturition defects,
and cancer progression. Up to now, the major side effect of LXRs is a
hypertriglyceridemia due to their activity in the liver on the fatty acid
synthase. In analogy with what was done for the estrogen receptors, it
is likely that SLiMs (Selective Liver X Receptor Modulators) need to be
developed [66]. They should have tremendous therapeutical possi-
bilities, after having successfully undergone the extensive approval
process. In a near future…Acknowledgments
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